Combination therapy for treating or managing acute myelocytic leukemia

Abstract

The present invention relates to methods and compositions designed for the treatment, management or prevention of cancer. The methods of the invention comprise the administration of an effective amount of one or more inhibitors of JNK in combination with the administration of an effective amount of one or more other agents useful for cancer therapy. The invention also provides pharmaceutical compositions comprising one or more inhibitors of JNK in combination with one or more other agents useful for cancer therapy. In particular, the invention is directed to methods of treatment and prevention of cancer by the administration of an effective amount of one or more inhibitors of JNK in combination with standard and experimental chemotherapies, hormonal therapies, bone marrow transplants, stem cell replacement therapies, biological therapies / immunotherapies and / or radiation therapies for treatment or prevention of cancer. Also included are methods of treatment of cancer by the administration of one or more inhibitors of JNK in combination with surgery, alone or in further combination with standard and experimental chemotherapies, hormonal therapies, bone marrow transplants, stem cell replacement therapies, biological therapies / immunotherapies and / or radiation therapies.

Description

[0001] This application is a continuation of U.S. application Ser. No. 10 / 384,440, filed Mar. 7, 2003, which claims the benefit of U.S. provisional application 60 / 362,705, filed Mar. 8, 2002, the disclosures of which are incorporated by reference herein in their entireties.1. FIELD OF THE INVENTION [0002] The invention relates to combination therapies for the treatment, prevention or management of a disease or disorder in cancer patients or patients having other proliferative diseases or disorders. 2. BACKGROUND OF THE INVENTION Jun N-Terminal Kinase (JNK) [0003] The Jun N-terminal kinase (JNK) pathway is activated by exposure of cells to environmental stress or by treatment of cells with pro-inflammatory cytokines and growth factors. Targets of the JNK pathway include the transcription factors c-jun and ATF2 (Whitmarsh A. J., and Davis R. J. J Mol. Med. 74:589-607, 1996). These transcription factors are members of the basic leucine zipper (bZIP) group that bind as homo- and hetero...

AI Technical Summary

Benefits of technology

[0015] The present invention is based, in part, on the recognition that inhibitors of JNK potentiate and synergize with, enhance the effectiveness of, improve the tolerance of, and / or reduce side effects caused by, other cancer therapies, including conventional and experimental chemotherapies, hormonal therapies, bone marrow transplants, stem cell replacement therapies, biological therapies / immunotherapies and radiation therapies. Thus, the invention encompasses treatment regimens or protocols that provide better therapeutic profiles than current single agent therapies or current combination therapy regimens. Encompassed by the invention are combination therapies that have additive potency or an additive therapeutic effect. The invention also encompasses synergistic combinations where the therapeutic efficacy is greater than additive. Preferably, such combinations also reduce or avoid unwanted or adverse effects. In certain embodiments, the combination therapies encompassed by the invention provide an improved overall therapy relative to administration of either a JNK inhibitor or any other cancer therapy alone. Given the invention, in certain embodiments, doses of existing or experimental cancer therapies can be reduced or administered less frequently which increases patient compliance, improves therapy and reduces unwanted or adverse effects.

Problems solved by technology

Thus, JNK inhibitors may block transformation and tumor cell growth.

Stroke is the 3rd leading cause of death and a leading cause of disability in the U.S. Stroke, along with neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's disease (PD) impose a huge burden on the health care industry by impacting the quality of life of those affected.

All of these approaches pose significant drawbacks for the patient.

Surgery, for example, may be contraindicated due to the health of the patient or may be unacceptable to the patient.

Additionally, surgery may not completely remove the neoplastic tissue.

Radiation therapy is only effective when the neoplastic tissue exhibits a higher sensitivity to radiation than normal tissue, and radiation therapy can also often elicit serious side effects.

Biological therapies / immunotherapies are limited in number and may produce side effects such as rashes or swellings, flu-like symptoms, including fever, chills and fatigue, digestive tract problems or allergic reactions.

Other agents, specifically colchicine and the vinca alkaloids, such as vinblastine and vincristine, interfere with microtubule assembly resulting in mitotic arrest.

Despite the availability of a variety of chemotherapeutic agents, chemotherapy has many drawbacks (see, for example, Stockdale, 1998, “Principles Of Cancer Patient Management” in Scientific American Medicine, vol.

Almost all chemotherapeutic agents are toxic, and chemotherapy causes significant, and often dangerous, side effects, including severe nausea, bone marrow depression, immunosuppression, etc.

Thus, because of drug resistance, many cancers prove refractory to standard chemotherapeutic treatment protocols.

Further, it is uncommon for cancer to be treated by only one method.

Images